Dova Pharmaceuticals (DOVA) Misses Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Dova Pharmaceuticals Reports Third Quarter 2017 Operating and Financial Results
November 9, 2017 4:05 PM ESTNDA for avatrombopag submitted to FDA
Conference call scheduled for 4:30 p.m. EST today
DURHAM, N.C., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today reported its operating and financial results for the quarter ended September 30, 2017.
Third Quarter and Recent Highlights
Submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Dova's drug candidate, avatrombopag, for the treatment of thrombocytopenia in... More